Dendrite Announces Grant under New Hire Authorization.

BEDMINSTER, N.J. -- Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today announced that stock options covering an aggregate of 100,000 shares of common stock were granted to Carl Cohen on June 28, 2006 in connection with his appointment as President, Marketing Services, and stock options covering an aggregate of 25,000 shares were granted to Ronald Pearce on June 26, 2006 in connection with his appointment as Vice President and Corporate Controller. The Company also announced that stock options covering an aggregate of 30,000 shares of common stock were granted to one non-executive officer employee on April 24, 2006 and options covering an aggregate of 7,000 shares were granted to two non-executive officer employees on February 3, 2006.

All such option grants were made under the Company's New Hire Authorization as inducements to entering into employment with the Company. All options granted include a ten-year duration and an exercise price equal to the closing price of Dendrite's stock on the business day immediately preceding the date of grant. The vesting schedule for the options is as follows: (i) twenty-five percent (25%) of the options shall first become exercisable on the first anniversary of date of grant and (ii) the remaining seventy-five percent (75%) shall become exercisable pro rata over the following three (3) year period, on a monthly basis, commencing on the first anniversary of the date of grant and ending on the fourth anniversary of the date of grant.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) provides sales, marketing, clinical and compliance solutions for the global, pharmaceutical industry. Dendrite has clients in more than 50 countries, including the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.